Duyuru • May 20
Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million. Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million.
Security Name: Common Units
Security Type: Equity/Derivative Unit
Securities Offered: 11,160,000
Price\Range: $0.5
Discount Per Security: $0.035
Security Name: Pre-Funded Units
Security Type: Equity/Derivative Unit
Securities Offered: 840,000
Price\Range: $0.49999
Discount Per Security: $0.03499 Duyuru • Apr 01
Sunshine Biopharma, Inc. announced delayed annual 10-K filing On 03/31/2026, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Feb 06
Sunshine Biopharma Inc. Announces Resignation of Abderrazzak Merzouki as Chief Operating Officer, Effective from February 5, 2026 Sunshine Biopharma Inc. announced that Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective from February 5, 2026. Duyuru • Oct 24
Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025 Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025. Duyuru • Aug 05
Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million. Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 15,577,965
Price\Range: $2.07 Duyuru • Apr 01
Sunshine Biopharma, Inc. announced delayed annual 10-K filing On 03/31/2025, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Jan 15
Sunshine Biopharma, Inc. Appoints Michel Roy as Its New Chief Commercial Officer Sunshine Biopharma Inc. announced the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives. In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutical industry, Mr. Roy has held various leadership positions at major international pharmaceutical companies, where he successfully led teams to achieve significant revenue growth and market expansion.
From 2020 to 2024, Mr. Roy founded and led the Canadian operations of Shilpa Medicare Ltd., a prominent pharmaceutical company based in Raichur, Karnataka, India. Shilpa specializes in manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations, with a strong presence in oncology APIs, drug delivery systems, peptides, and specialty chemicals. Previously, from 2014 to 2020, Mr. Roy was Vice President, Business Development and Sales for Intas Pharmaceuticals Ltd., a major pharmaceutical company with a strong presence in over 85 countries. Intas is headquartered in Ahmedabad, India. While at Intas, Mr. Roy was responsible for the strategic planning, business development, sales, financial management and regulatory affairs. At the beginning of his career, Mr. Roy worked as a consultant for various international Contract Research Organization (CRO) companies. Mr. Roy is a results-driven professional with considerable business development experience in the pharmaceutical and biotechnology sectors including licensing, sales, regulatory affairs, operations and program management. His strong negotiation and communication skills, coupled with an in-depth knowledge of all facets of the drug development process contribute to a stellar reputation as a dynamic leader who produces superior results. Mr. Roy received his Executive Master of Business Administration (EMBA) from John Molson School of Business (Concordia University) in 2010 and his Master of Science (M.Sc.) from Université de Montréal in 1999. He also received a Bachelor of Commerce degree with a major in economics from Concordia University in 1990. Duyuru • Dec 10
Sunshine Biopharma Inc. Announces Novel Inhibitor for SARS Coronavirus Sunshine Biopharma Inc. announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-1 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV- 2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent rapid disease progression and reduce hospitalization. PLpro is an alternative therapeutic target for developing antiviral compounds against proteolytic processing activity of SARS-CoV- two. PLpro is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection, leading to a more severe disease outcome. In August 2024, Sunshine Biopharma published initial research results on its PLpro inhibitors library in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, Sunshine Biopharma's current lead compound was recently found to be active at sub-micromolar concentrations against PLpro and exhibited antiviral activity in SRAS-CoV-2 infected cells as well as in cells infected with several different VOC. In addition, the Company's lead compound had favorable pharmacokinetics properties inrod species and exhibited preferred drug accumulation in the lungs over plasma. The compound was found to beally active in a K18-human-ACE2 transgenic mouse model and to significantly reduce virus load in the lungs of infected animals in a dose-dependent manner without gross toxicities. This research is being carried out in collaboration with the University of Arizona. Duyuru • Dec 02
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma Sunshine Biopharma Inc. announced that it has completed mouse model studies providing proof-of-concept for the Company's K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several systematic treatment options were available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%. When transfected into cultured human HCC cell lines and patient-derived HCC cells, K1.1 mRNA exhibited dose-dependent anti-proliferative activity in vitro. Following encapsulation in specifically engineered lipids, the resulting K1.1 mRNA-Lipid Nanoparticles (K1.1/LNP) were efficiently delivered to livers of mice in a dose-dependent manner in vivo. K1.1/LNP, under repeated systemic dosing, was found to reduce growth of two different types of human HCC tumors orthotopically grafted into the livers of immunodeficient mice. The pharmacodynamics of K1.1/LNP in intrahepatic tumors was well correlated with antitumor efficacy in mice. Duyuru • Oct 18
Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024 Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024. Duyuru • Sep 05
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry Sunshine Biopharma, Inc. announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection. There are still unmet medical needs to combat SARS-CoV-2 infection. SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent disease rapid progression and reduce hospitalization. PLpro is a compelling therapeutic target for developing antiviral compounds against SARS-CoV-2. It is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection by the virus. The active site of an enzyme is almost always the primary target for drug design. PLpro eluded scientist for many years due to its featureless active site. To address the challenge of PLpro's indistinct active site, designed and synthesized a noncovalent inhibitor library targeting a vulnerability in PLpro remote from the active site incorporating the "BL2-groove", a key feature discovered by project co-lead, Prof. Rui Xiong of the University of Arizona. One of the 50 compounds, XR8-23 (Compound 10), had an enzyme inhibition activity (IC50) of 0.39 µM and exhibited a broad spectrum of antiviral activity towards at least 4 strains of VOC including WA1/2020, Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1). It had over 10-fold of selective accumulation in the lungs than in plasma and exhibited in vivo activity in a mouse-adapted SARS-CoV-2 infection (MA10) at 10 mg/kg by repeated IV injections. Duyuru • Aug 15
Sunshine Biopharma, Inc. announced delayed 10-Q filing On 08/14/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Aug 07
Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing Sunshine Biopharma, Inc. announced a one for twenty reverse split of its common stock, effective at market open on August 8, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. Duyuru • Jun 08
Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101 On June 7, 2024, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’), that based on further review of the Company’s public filings with the Securities and Exchange Commission and supporting materials submitted to Nasdaq, its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the ‘alternative cashless exercise’ provision of the Series A warrants the Company issued on February 15, 2024, raises public interest and investor protection concerns because the issuance of Series A warrants resulted in substantial dilution for the stockholders of the Company to date and may cause potential future dilution. Accordingly, as set forth in the letter, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. As set forth in the letter, under the ‘alternative cashless exercise’ provision set forth in Section 2.3 of the Series A warrants the holder of the Series A warrant, has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise of the Series A warrant and (y) 2. However, this multiplier was not proportionally adjusted to 0.02 in connection with the 1-for-100 reverse stock split the Company implemented on April 17, 2024, but instead it remained unchanged at 2. As set forth in the letter, a reverse stock split has the effect of increasing the stock price by proportionally consolidating the outstanding shares; however, the number of shares issuable to Series A warrant holders under the ‘alternative cashless exercise’ provision were not so consolidated. As such, shareholders of the Company were substantially diluted, while the holders of the Series A warrants were enriched one-hundred fold. Moreover, in the event the Company effects another reverse stock split, the shareholders of the Company will be diluted even further to the benefit of the Series A warrant holders. For these reasons, in order to protect investors and the public interest, Nasdaq Rule 5101 empowers Nasdaq to apply additional and more stringent criteria for the continued listing of securities, or to suspend or delist particular securities, based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. The letter has no immediate effect on the listing of the Company’s common stock. The letter serves as a formal notification that the Nasdaq Hearings Panel (the ‘Panel’) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market. In that regard, the letter states that the Company should present its views with respect to this additional deficiency to the Panel in writing no later than June 14, 2024. Duyuru • May 17
Sunshine Biopharma, Inc. announced delayed 10-Q filing On 05/15/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • Mar 31
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: US$0.18 loss per share (improved from US$1.76 loss in FY 2022). Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed 83% from FY 2022). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US. Duyuru • Mar 04
Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement As previously disclosed, on March 24, 2023, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the ‘Minimum Bid Price Requirement’). On September 21, 2023, the Company received another notification letter from Nasdaq advising that Nasdaq’s staff had determined that the Company was eligible for an extension of an additional 180 calendar day period, or until March 18, 2024, to cure the bid price deficiency. On February 28, 2024, the Company received a notification letter from Nasdaq advising that Nasdaq’s staff had determined that as of February 27, 2024, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the ‘Low Priced Stocks Rule’). Accordingly, Nasdaq determined to remove the Company’s securities from listing and registration on The Nasdaq Stock Market, subject to the procedures set in the Nasdaq Listing Rule 5800 Series which provide the Company with the opportunity to appeal this determination. If the Company failed to file such appeal by March 6, 2024, trading of the Company’s common stock would be suspended at the opening of business on March 8, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the ‘SEC’), which would remove the Company’s securities from listing and registration on The Nasdaq Stock Market. On February 28, 2024, the Company submitted such appeal, and a hearing has been scheduled for April 25, 2024. Accordingly, the delisting action referenced in the Nasdaq staff’s determination letter has been stayed, pending a final written decision by the Nasdaq Hearings Panel. The Company has received shareholder approval for and intends to effect a 40-for-1 reverse stock split 20 days after the mailing of its definitive information statement (the preliminary form of which was filed with the SEC on February 21, 2024) to shareholders, to regain compliance with the Minimum Bid Price Requirement. There is no assurance the Company will regain compliance with the Minimum Bid Price Requirement. New Risk • Feb 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 141% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Market cap is less than US$10m (US$3.46m market cap). New Risk • Feb 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (340% increase in shares outstanding). Market cap is less than US$10m (US$6.84m market cap). Duyuru • Jan 31
Sunshine Biopharma, Inc. Announces Executive Changes On January 25, 2024, the Board of Directors of Sunshine Biopharma, Inc. held its annual meeting. At the meeting the company elected Dr. Abderrazzak Merzouki as Chief Science Officer, Mr. Marc Beaudoin as Chief Operating Officer, and Mr. Malek Chamoun as Chief Development Officer. Previously, Dr. Merzouki had held the position of Chief Operating Officer. Mr. Beaudoin and Mr. Chamoun are new officers. The other officers are continuing in their prior positions. Mr. Chamoun is also currently President of the Company’s wholly owned subsidiary, Nora Pharma Inc. The resumes of the Company’s new officers are as follows: Malek Chamoun, age 39,was appointed as Chief Development Officer in January 2024. In 2017 he founded Nora Pharma Inc., a Canadian pharmaceutical company (“Nora Pharma”), based in Montreal, where he has been the President and CEO since inception. The company acquired Nora Phara in October 2022. Mr. Chamoun received a bachelor’s degree in business administration from Hautes Études Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012. He devotes all of his business time to Nora’s affairs. Marc Beaudoin, age 57, was appointed as Chief Operating Officer in January 2024. Mr. Beaudoin has been self-employed as a business strategy consultant, primarily in the pharmaceutical and biopharmaceutical sectors, since 2016. From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and Communications, Strategic Planning, Business Development & Portfolio Management. As an executive and an entrepreneur, he combines expertise in strategic planning with operational and commercial execution. Mr. Beaudoin obtained his MBA from Sherbrooke University in 2018. He also holds multiple certifications (including a fellowship) from the Association for Supply Chain Management. Reported Earnings • Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations Third quarter 2023 results: US$0.025 loss per share (improved from US$0.077 loss in 3Q 2022). Revenue: US$5.96m (up US$5.82m from 3Q 2022). Net loss: US$651.5k (loss narrowed 55% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Duyuru • Oct 19
Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023 Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect five persons to Board of Directors, until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to consider and ratify the appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accountant to audit the Company’s financial books and records for its fiscal year ending December 31, 2023; to consider and approve the Company’s 2023 Equity Incentive Plan. Duyuru • Sep 23
Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance Sunshine Biopharma Inc. (the "Company") announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. The Nasdaq staff has determined that Sunshine Biopharma is eligible, based on the Company meeting the continued listing requirements for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time before March 18, 2024, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "SBFM". Reported Earnings • Aug 13
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.036 loss per share (further deteriorated from US$0.034 loss in 2Q 2022). Revenue: US$5.56m (up US$5.41m from 2Q 2022). Net loss: US$902.1k (loss widened 67% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 75%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Duyuru • May 17
Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding On May 16, 2023, Sunshine Biopharma, Inc. closed the transaction. In connection with the sale of the securities described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder for transactions not involving a public offering. Reported Earnings • May 11
First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022) First quarter 2023 results: US$0.077 loss per share. Revenue: US$4.89m (up US$4.77m from 1Q 2022). Net loss: US$1.70m (loss widened 38% from 1Q 2022). Reported Earnings • Apr 08
Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021) Full year 2022 results: US$1.76 loss per share. Revenue: US$4.35m (up US$4.12m from FY 2021). Net loss: US$26.7m (loss widened 115% from FY 2021). Duyuru • Jan 20
Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares. Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces a share repurchase program. Under the program, the company will repurchase up to $2 million worth of its shares. As of November 7, 2022, the company had approximately 22,600,000 shares of common stock issued and outstanding. Reported Earnings • Nov 09
Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021) Third quarter 2022 results: US$0.077 loss per share (improved from US$1.59 loss in 3Q 2021). Net loss: US$1.46m (loss narrowed 64% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 04
Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021) Second quarter 2022 results: US$0.034 loss per share (up from US$1.20 loss in 2Q 2021). Net loss: US$538.9k (loss narrowed 81% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Reported Earnings • May 07
First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021) First quarter 2022 results: US$0.23 loss per share (up from US$2.82 loss in 1Q 2021). Net loss: US$1.24m (loss narrowed 80% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Board Change • Feb 22
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Rabi Kiderchah was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Feb 16
Sunshine Biopharma Common Stock Deleted from Other OTC Sunshine Biopharma, Inc. Common Stock has been deleted from Other OTC effective from February 15, 2022, due to Market Center Change Listed on NASDAQ. Duyuru • Jun 10
Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as Planned Sunshine Biopharma Inc. confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned. The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death. Should these studies prove successful, the Company plans to file the data with the FDA and request authorization to do testing in actual COVID-19 patients. Sunshine Biopharma’s protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. Duyuru • May 26
Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types Sunshine Biopharma Inc. announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply. Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity. Among these are the vinca alkaloids (vinblastine and vincristine), the taxanes (paclitaxel and docetaxel), the anthracyclines (doxorubicin and daunorubicin), the topoisomerase inhibitors (topotecan and etoposide), and the tyrosine kinase inhibitors (dasatinib and gefitinib). Sunshine Biopharma’s P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs. In addition, it has been recognized that most cancers consist of a heterogeneous population of drug-sensitive and drug-resistant cells. During the course of current chemotherapy regiments, drug-sensitive cells are selectively destroyed and resistant cells become the dominant cancer cell population, leading to recurrence and metastasis. Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated. Duyuru • Apr 24
Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc. Sunshine Biopharma, Inc. (OTCPK:SBFM) announced that it has received $500,000 in a round funding from returning investor RB Capital Partners, Inc. on April 22, 2021. Duyuru • Mar 06
Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing Sunshine Biopharma Inc. announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies. Duyuru • Aug 15
Sunshine Biopharma, Inc. announced delayed 10-Q filing On 08/14/2020, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 
